SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a pacesetter in AI options for scientific trials, in the present day introduced outcomes from a collaboration with remynd, a Belgium-based biotech firm creating therapies for neurodegenerative ailments. The outcomes had been shared on the 2025 Alzheimer’s & Parkinson’s Drug Improvement Summit in Boston.
The collaboration centered on remynd’s Part 2a scientific trial of REM127, an investigational, first-generation small molecule remedy concentrating on septins in sufferers with mild-to-moderate Alzheimer’s Illness (AD). The examine enrolled a restricted variety of individuals and measured modifications in AD biomarkers over a brief remedy window.
Unlearn supported the examine by making use of its Alzheimer’s Illness-specific Digital Twin Generator (AD DTG)—a proprietary machine studying mannequin educated on information from greater than 26,000 individuals throughout landmark AD datasets comparable to ADNI, CPAD, NACC, and EPAD. The AD DTG makes use of every participant’s baseline information to forecast their scientific and biomarker trajectories underneath customary care, producing a “digital twin” for each particular person within the trial.
These digital twins served as individualized comparators, offering a further layer of proof to assist interpret modifications noticed within the handled inhabitants. This method is especially beneficial in early-phase research the place small pattern sizes restrict the power to attract conclusions utilizing conventional statistical strategies alone.
“It is a highly effective instance of how digital twins will help unlock insights from small research,” mentioned Steve Herne, CEO of Unlearn. “Our collaboration with remynd helped strengthen the proof behind REM127 and demonstrated the worth of utilizing AI to assist smarter, sooner scientific analysis.”
“The collaboration with Unlearn and the ensuing information additional will increase our confidence in our pioneering method in the direction of attaining symptomatic aid and illness modification in Alzheimer’s. This may assist our efforts to advance an optimized second-generation remedy,” mentioned Gerard Griffioen, Ph.D., CSO of remynd. “Digital twins provide a brand new lens for deciphering biomarker developments over time—particularly in early-stage trials the place each information level issues.”
For extra info, go to www.unlearn.ai or comply with us on LinkedIn and X/Twitter.
